MEI Pharma Announces Private Placement for $100 Million Litecoin Treasury Strategy

The post MEI Pharma Announces Private Placement for $100 Million Litecoin Treasury Strategy appeared first on Coinpedia Fintech News

MEI Pharma has announced a $100 million private investment at $3.42 per share, marking a bold step forward in its growth strategy. As part of the deal, Charlie Lee, creator of Litecoin, will join MEI’s Board of Directors, replacing Taheer Datoo.

MEI has also appointed GSR as its digital asset and treasury advisor to help launch its new Litecoin Treasury Strategy, with a unique blend of biotech and blockchain.

The $100M funding round was also backed by the Litecoin Foundation and top crypto firms like MOZAYYX, ParaFi, Hivemind, and CoinFund. Notably, MEI becomes the first public company to adopt Litecoin as a treasury reserve asset. Litecoin is a fast, reliable cryptocurrency often called the “silver to Bitcoin’s gold.”

Litecoin’s perfect track record and real-world use make it a solid, decentralized asset for MEI’s treasury strategy.

“This milestone not only reflects growing institutional confidence in LTC but also sets the stage for broader adoption in traditional capital markets,” Lee said in the press release.

Charlie notes that for 14 years, Litecoin has been a stable, low-cost, and accessible network used by millions. It leads in global transactions on platforms like BitPay and is trusted for payments, remittances, and retail. This partnership with GSR and MEI Pharma brings Litecoin’s real-world utility into the institutional space for the first time.

There has been a growing list of companies adding crypto to their balance sheets.This shift shows that crypto is being viewed as a long-term strategic asset, and not just a speculative one. MEI’s move signals a belief in Litecoin’s future as a real-world payment tool, and not just a digital store of value.

Deal Set to Close July 22

MEI Pharma plans to close its $100 million private investment deal by July 22, 2025, pending final approvals. The funds will be used to buy Litecoin, which will become MEI’s primary treasury reserve asset. Titan Partners Group is acting as the sole placement agent for the deal.

MEI stated that the PIPE was designed to meet Nasdaq’s listing and minimum pricing rules. After the deal closes, the company will file a resale registration statement with the SEC.

MEI’s Stock Surges

MEI Pharma’s stock jumped 83% in pre-market trading on Friday after the announcement. Shares hit a high of $9 before pulling back and are currently trading at $5.91, up 31% in the last 24 hours.

Tällä sivulla näytettävä sisältö on kolmansien osapuolten tarjoamaa. Ellei toisin mainita, OKX ei ole lainatun artikkelin / lainattujen artikkelien kirjoittaja, eikä OKX väitä olevansa materiaalin tekijänoikeuksien haltija. Sisältö on tarkoitettu vain tiedoksi, eikä se edusta OKX:n näkemyksiä. Sitä ei ole tarkoitettu minkäänlaiseksi suositukseksi, eikä sitä tule pitää sijoitusneuvontana tai kehotuksena ostaa tai myydä digitaalisia varoja. Siltä osin kuin yhteenvetojen tai muiden tietojen tuottamiseen käytetään generatiivista tekoälyä, tällainen tekoälyn tuottama sisältö voi olla epätarkkaa tai epäjohdonmukaista. Lue aiheesta lisätietoa linkitetystä artikkelista. OKX ei ole vastuussa kolmansien osapuolten sivustojen sisällöstä. Digitaalisten varojen, kuten vakaakolikoiden ja NFT:iden, omistukseen liittyy suuri riski, ja niiden arvo voi vaihdella merkittävästi. Sinun tulee huolellisesti harkita, sopiiko digitaalisten varojen treidaus tai omistus sinulle taloudellisessa tilanteessasi.